[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628026":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":38,"responsibleParty":52,"collaborators":26,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":26,"enrollmentInfo":63,"targetDuration":26,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":41,"whyStopped":26,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Hospital Universitari Vall d'Hebron Research Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Early discharge (24 hours post-TAVI)","EXPERIMENTAL","Patients will be discharged from the hospital 24 hours post-TAVI with PhysioMem PM 100 4G ambulatory monitoring system.",[13],"Device: PhysioMem PM 100 4G ambulatory monitoring system",{"label":15,"type":16,"description":17,"interventionNames":18},"Discharge according Standard Care","ACTIVE_COMPARATOR","Patients will be discharged from the hospital according standard care",[19],"Behavioral: Standard care",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BEHAVIORAL","Standard care","Patients discharged according to standard care",[15],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"DEVICE","PhysioMem PM 100 4G ambulatory monitoring system","Patients discharged with PhysioMem PM 100 4G ambulatory monitoring system",[9],[33],{"name":34,"role":35,"phone":36,"phoneExt":26,"email":37},"Bruno García del Blanco, MD, PhD","CONTACT","00342746155","bruno.garcia@vallhebron.cat",[39],{"facility":40,"status":41,"city":42,"state":26,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":26},"Hospital Unniversitari Vall d'Hebron","RECRUITING","Barcelona","08035","Spain","ES",{"type":47,"coordinates":48},"Point",[49,50],2.15899,41.38879,{"lat":50,"lon":49},{"type":53,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100628026","pilot-study-to-evaluate-a-noninvasive-electrocardiographic-monitoring-strategy-associated-with-early-discharge-in-patients-with-conduction-disorders-following-tavi-implantation-improve-study-100628026",false,"NCT07456280","Pilot Study to Evaluate a Noninvasive Electrocardiographic Monitoring Strategy Associated With Early Discharge in Patients With Conduction Disorders Following TAVI Implantation (IMPROVE Study)","IMPROVE","Inclusion Criteria:\n\nAll inclusion criteria must be met\n\n* Age ≥ 18 years and\n* Undergone successful transfemoral or transaortic TAVI for severe aortic stenosis and\n* Presence of at least one of the following conduction disorders and\n* Pre-procedural basal conduction disorder (e.g., right\u002Fleft bundle branch block, bifascicular block, IVCD) with QRS between 120-160 msec.\n* De novo conduction disorder after TAVI (de novo bundle branch block) with QRS between 120-160 msec.\n* Clinical stability at 24 hours post-procedure and\n* Capacity to give informed consent.\n\nExclusion Criteria:\n\nNo exclusion criteria must be met\n\n* Immediate indication for permanent pacemaker following the procedure.\n* Persistent complete atrioventricular block.\n* QRS \\>160 msec and\u002For PR prolongation.\n* Haemodynamic instability or complications of TAVI (major bleeding, stroke, decompensated heart failure) that contraindicate early discharge.\n* Technical or clinical impossibility of using the PhysioMem PM 1004G monitoring system.\n* Life expectancy \\\u003C 12 months due to non-cardiovascular comorbidity.\n* Refusal or inability to undergo outpatient follow-up.\n* Pregnant or breastfeeding.","ALL","18 Years",{"count":64,"type":65},100,"ESTIMATED","INTERVENTIONAL",[68],"NA","Study to evaluate the efficacy and safety of a non-invasive electrocardiographic monitoring strategy associated with early discharge in patients with conduction disorder after transfemoral TAVI implantation, and its potential benefits compared to standard care.",[71,72],"Severe Aortic Valve Stenosis","Cardiovascular Diseases",[74],"TAVI(Transcatheter Aortic Valve Implantation)","2026-07-20",{"date":77,"type":78},"2026-07-22","ACTUAL",{"date":75,"type":78},{"date":81,"type":65},"2028-08-01",{"name":5,"class":6},1]